A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light.

China’s Innovent Biologics forged a licensing agreement with biosimilar-focused Coherus BioSciences to commercialize Innovent’s biosimilar candidate to Avastin (bevacizumab) in the United States and Canada.

The European Commission granted conditional marketing authorization for Libtayo (cemiplimab) for treating adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.

With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.

Cancer drug study patients tend to be younger than most people with the disease in the general population.

Bristol-Myers Squibb Company announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.

There was a flurry of activity during the first few days of the American Society of Clinical Oncology, with multiple presentations made showing the benefits of various oncology treatments.

The IQVIA Institute for Human Data Science is releasing the 2019 “Global Oncology Trends” report simultaneously with the American Society of Clinical Oncology (ASCO) Meeting.

At the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU), companies have showcased more clinical data in presentations for prostate cancer treatment.

Astellas Pharma announced that the company is wrapping up its research operations with Santa Monica, Calif.-based Agenus.